

Financial news for SCYX dated on 2020-05-11: SCYNEXIS Q1 EPS \$(0.070) Up From \$(0.460) YoY

Financial news for SCYX dated on 2020-05-06: SCYNEXIS Highlights 6 Abstracts Published By ECCMID Related To Potential Clinical Utility Of Ibrexafungerp

Financial news for SCYX dated on 2020-04-23: Aegis Capital Maintains Buy on SCYNEXIS, Raises Price Target to \$4.5

Financial news for SCYX dated on 2020-04-23: 20 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for SCYX dated on 2020-04-21: SCYNEXIS Shares To Resume Trade At 7:30 a.m. EDT

Financial news for SCYX dated on 2020-04-21: SCYNEXIS Announces Ibrexafungerp Achieved Statistically Significant Superiority Over Placebo For Primary And Key Secondary Study Endpoints

Financial news for SCYX dated on 2020-04-21: SCYNEXIS Shares Halted, News Pending

Financial news for SCYX dated on 2020-04-13: SCYNEXIS, Aspire Capital Report \$20M Common Stock Purchase Deal

Financial news for SCYX dated on 2020-04-12: The Week Ahead In Biotech: Urogen FDA Decision, Amarin, J&J Earnings And More COVID-19 Updates

Financial news for SCYX dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latest Stage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for SCYX dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for SCYX dated on 2020-03-13: The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

Financial news for SCYX dated on 2020-03-05: SCYNEXIS Reports Preclinical Data On Ibrexafungerp, Azoles Against Aspergillus Presented At Advances Against Aspergillosis and Mucormycosis Conference

Financial news for SCYX dated on 2020-02-13: SCYNEXIS Completes Patient Enrollment Ahead Of Schedule In Second Pivotal Phase 3 Study Of Oral Ibrexafungerp For The Treatment Of Vulvovaginal Candidiasis

Financial news for SCYX dated on 2020-01-22: 18 Drug Manufacturers--Specialty & Generic Stocks Moving In Wednesday's Session

Financial news for SCYX dated on 2020-01-08: 50 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for SCYX dated on 2020-01-08: SCYNEXIS Announces Results From Second Interim Analysis Of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability To Treat Severe Fungal Infections In The Hospital Setting

Financial news for SCYX dated on 2019-12-18: 30 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for SCYX dated on 2019-12-17: 19 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for SCYX dated on 2019-12-16: Scynexis CEO Taglietti Buys 333,334 @ Avg Price: \$0.45

Financial news for SCYX dated on 2019-12-10: 41 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for SCYX dated on 2019-12-10: The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy \$3M In ContraFect Shares

Financial news for SCYX dated on 2019-11-12: SCYNEXIS Q3 EPS \$(0.14) Down From \$0.01 YoY

Financial news for SCYX dated on 2019-11-07: SCYNEXIS Shares Resume Trade, Up 21%

Financial news for SCYX dated on 2019-11-07: SCYNEXIS Shares To Resume Trade At 8:30 a.m. EST

Financial news for SCYX dated on 2019-11-07: SCYNEXIS Says Second Phase 3 Study Of Ibrexafungerp On Track For Top-Line Results In Early Q2'20, Supporting NDA Submission In H2'20

Financial news for SCYX dated on 2019-11-07: SCYNEXIS Reports Ibrexafungerp For Vulvovaginal Candidiasis Achieved Highly Statistically Significant Superiority Over Placebo For Primary Endpoint, Was Generally Safe, Well Tolerated

Financial news for SCYX dated on 2019-11-07: SCYNEXIS Shares Halted News Pending

Financial news for SCYX dated on 2019-11-04: 24 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for SCYX dated on 2019-10-31: SCYNEXIS Announces Oral Presentation of Data From Ibrexafungerp Phase 2b DOVE Study At The 3rd ISIDOG Congress Oct. 31-Nov. 1

Financial news for SCYX dated on 2019-10-24: SCYNEXIS Reports Amendment To Protocol For Ongoing FURI Study Probing Safety, Efficacy Of Oral Ibrexafungerp As Salvage Treatment For Patients With Resistant, Refractory Severe Fungal Infections

Financial news for SCYX dated on 2019-10-10: SCYNEXIS Reports Non-Dilutive Funding Through New Jersey Economic Development Authority Net Operating Loss, R&D Tax Credits Program; Expects To Receive \$3.3M In Cash By End Of 2019

Financial news for SCYX dated on 2019-09-18: SCYNEXIS Completes Last-Patient/Last-Visit Ahead Of Schedule In First Phase 3 Study Of Oral Ibrexafungerp For Treatment Of Vulvovaginal Candidiasis

Financial news for SCYX dated on 2019-07-24: SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement With FDA For Phase 3 Study Evaluating Oral Ibrexafungerp For Prevention Of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study)

Financial news for SCYX dated on 2019-05-30: SCYNEXIS Reports Completion Of Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration Of Ibrexafungerp

Financial news for SCYX dated on 2019-05-08: SCYNEXIS Q1 EPS \$(0.46) Misses \$(0.2) Estimate, Sales \$64K Miss \$90K Estimate

Financial news for SCYX dated on 2019-04-25: SCYNEXIS Mentioned In Chemotherapy Journal Article

Financial news for SCYX dated on 2019-04-16: The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives

Financial news for SCYX dated on 2019-04-13: The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Financial news for SCYX dated on 2019-04-08: SCYNEXIS shares are trading higher after the company commended the New York Times for reporting on Candida auris and the major global health issues caused by drug-resistant pathogens.

Financial news for SCYX dated on 2019-04-07: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

Financial news for SCYX dated on 2019-04-03: SCYNEXIS Reports Its Ibrexafungerp Showed Favorable Clinical Activity In Resistance Fungal Infections In Data Presented At ECCMID

Financial news for SCYX dated on 2019-03-22: SCYNEXIS S-3 Shows Registration For 13.008M Common Shares

Financial news for SCYX dated on 2019-03-14: SCYNEXIS Provides Company Update

Financial news for SCYX dated on 2019-02-01: Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Fri., Feb. 1, 2019

Financial news for SCYX dated on 2019-01-31: Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Thurs., Jan. 31, 2019

Financial news for SCYX dated on 2019-01-31: SCYNEXIS shares are trading higher after a Phase 3 study of ibrexafungerp showed the drug demonstrated efficacy in 17 of 20 patients with fungal infections.

Financial news for SCYX dated on 2019-01-30: SCYNEXIS shares are trading higher after a Phase 3 study of ibrexafungerp showed the drug demonstrated efficacy in 17 of 20 patients with fungal infections.

Financial news for SCYX dated on 2019-01-30: SCYNEXIS Reports Interim Results From Phase 3 Open-Label FURI Study Showed Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies

Financial news for SCYX dated on 2019-01-29: Scynexis Shares Trade Higher As Traders Circulate Medical Journal Mentioning The Company

Financial news for SCYX dated on 2019-01-04: The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO

Financial news for SCYX dated on 2019-01-03: UPDATE: SCYNEXIS Reports 'Received non-dilutive state incentive cash benefit of \$6.7 million; approximately \$51 million cash balance as of January 3, 2019, sufficient to ensure full funding of the VANISH Phase 3 VVC trials past top-line data'

Financial news for SCYX dated on 2019-01-03: SCYNEXIS Offers Year-End Update, Outlines 2019 Plans

Financial news for SCYX dated on 2018-12-30: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for SCYX dated on 2018-12-23: The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results

Financial news for SCYX dated on 2018-12-18: The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J \$5B Buyback Plan

Financial news for SCYX dated on 2018-12-14: The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch

Financial news for SCYX dated on 2018-12-13: The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen

Financial news for SCYX dated on 2018-12-12: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 11, 2018

Financial news for SCYX dated on 2018-12-12: The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel

Financial news for SCYX dated on 2018-12-04: Stocks Which Set New 52-Week Low Yesterday, Mon., Dec. 3, 2018

Financial news for SCYX dated on 2018-12-04: The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eisai Gets A New CFO

Financial news for SCYX dated on 2018-11-23: Stocks Which Set New 52-Week Low The Last Trading Session, Wed., Nov. 21, 2018

Financial news for SCYX dated on 2018-11-21: The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novilion CEO

Financial news for SCYX dated on 2018-11-19: Stocks Which Set New 52-Week Lows Fri., Nov. 16, 2018

Financial news for SCYX dated on 2018-11-16: Stocks Which Set New 52-Week Low Yesterday, Thurs., Nov. 16, 2018

Financial news for SCYX dated on 2018-11-14: The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut

Financial news for SCYX dated on 2018-11-13: Scynexis Q3 EPS \$0.01 Beats \$(0.18) Estimate, Sales \$64K Miss \$70K Estimate

Financial news for SCYX dated on 2018-11-13: The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut

Financial news for SCYX dated on 2018-10-24: The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering

Financial news for SCYX dated on 2018-10-23: Stocks Which Set New 52-Week Low Yesterday, October 22nd

Financial news for SCYX dated on 2018-10-23: SCYNEXIS Reports Completion Of End-Of-Phase 2 Meeting With FDA; FDA Has Agreed To Co.'s Overall Design Of Phase 3 Vulvovaginal Candidiasis Program For Oral Ibrexafungerp

Financial news for SCYX dated on 2018-10-23: UPDATE: SCYNEXIS Says Is On Target To Initiate Phase 3 Registration Program In Q4'18

Financial news for SCYX dated on 2018-10-23: SCYNEXIS Reports FDA Deal For Phase 3 Vulvovaginal Candidiasis Program For Oral Ibrexafungerp

Financial news for SCYX dated on 2018-10-23: The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares

Financial news for SCYX dated on 2018-10-15: SCYNEXIS, Inc. Announces First Patient Dosed In Phase 3 Open-label Study Evaluating Oral Ibrexafungerp In Candida auris Infections

Financial news for SCYX dated on 2018-08-22: Calyxt Names Dr. Yves J. Ribeill Interim CEO

Financial news for SCYX dated on 2018-08-09: SCYNEXIS Q2 EPS \$(0.23) Misses \$(0.17) Estimate, Sales \$64K Miss \$70K Estimate

Financial news for SCYX dated on 2018-07-10: SCYNEXIS Shars Up 24.9% After Hours Following Evidence Of Clinical Effectiveness Of Oral SCY-078 Shown In Phase 2b Study

Financial news for SCYX dated on 2018-07-10: UPDATE: Initiation Of Phase 3 Registration Program In VVC Planned For Q4 '18

Financial news for SCYX dated on 2018-07-10: SCYNEXIS Shares To Resume Trade At 4:35 p.m. EDT

Financial news for SCYX dated on 2018-07-10: UPDATE: SCYNEXIS Says Results Of Phase 2b Oral SCY-078 Study 'confirm strong clinical activity of oral SCY-078 and suggest improved sustained benefit relative to the standard of care'

Financial news for SCYX dated on 2018-07-10: SCYNEXIS Reports Results From Phase 2b Dose-Finding Study Of Oral SCY-078 In Vulvovaginal Candidiasis: 'Clinically and mycologically effective and well-tolerated...identified for use in Phase 3 registration program'

Financial news for SCYX dated on 2018-07-10: Scynexis Shares Halted News Pending

Financial news for SCYX dated on 2018-06-29: Canaccord Genuity Assumes SCYNEXIS at Buy, Announces Price Target \$4

Financial news for SCYX dated on 2018-06-27: UPDATE: SCYNEXIS Highlights 'SCY-078 has the potential to provide a safer treatment option for pregnant women experiencing fungal infections and for patients who may become pregnant while on antifungal therapy'

Financial news for SCYX dated on 2018-06-27: SCYNEXIS Reports SCY-078 Showed 'no impact on fertility or early embryonic development in pre-clinical studies, a differentiator vs. current treatments'

Financial news for SCYX dated on 2018-06-27: Maxim Group Initiates Coverage On SCYNEXIS with Buy Rating, Announces \$6 Price Target

Financial news for SCYX dated on 2018-06-06: UPDATE: SCYNEXIS Says 'On track to report Phase 2b data in VVC by Jul. 2018, with Phase 3 trial initiation in Q4'18'

Financial news for SCYX dated on 2018-06-06: UPDATE: SCYNEXIS Says Results For SCY-078 'suggest potential clinical relevance of SCY-078 for patients with Type 2 diabetes with VVC'

Financial news for SCYX dated on 2018-06-06: SCYNEXIS Reports Publication Of Phase 1 Study Results For SCY-078 In Journal Of Clinical Pharmacology: Showed 'low risk of interactions between SCY-078 and drugs metabolized by CYP enzymes'

Financial news for SCYX dated on 2018-05-25: 45 Biggest Movers From Yesterday

Financial news for SCYX dated on 2018-05-24: 42 Stocks Moving In Thursday's Mid-Day Session

Financial news for SCYX dated on 2018-05-24: Benzinga's Top Upgrades, Downgrades For May 24, 2018

Financial news for SCYX dated on 2018-05-24: Ladenburg Thalmann Initiates Coverage On SCYNEXIS with Buy Rating, Announces \$9 Price Target

Financial news for SCYX dated on 2018-05-08: SCYNEXIS Q1 EPS \$(0.12) Beats \$(0.21) Estimate, Sales \$64K Beat \$60K Estimate

Financial news for SCYX dated on 2018-05-07: Benzinga's Top Upgrades, Downgrades For

May 7, 2018

Financial news for SCYX dated on 2018-05-07: H.C. Wainwright Assumes SCYNEXIS at Buy, Announces Price Target \$5

Financial news for SCYX dated on 2018-05-01: SCYNEXIS Shares Up 4.2% After Co. Earlier Reported It Received FDA QIDP and Fast Track Designations For Its Oral SCY-078

Financial news for SCYX dated on 2018-05-01: SCYNEXIS Reports Oral SCY-078 Received FDA QIDP, Fast Track Designations For Treatment Of VVC, Prevention Of Recurrent VVC

Financial news for SCYX dated on 2018-04-26: Benzinga's Daily Biotech Pulse: Catabasis Soars On Trial Results, Eloxx Listing, Biomarin Earnings

Financial news for SCYX dated on 2018-04-10: Seaport Global Initiates Coverage On SCYNEXIS with Buy Rating, Announces \$4.00 Price Target

Financial news for SCYX dated on 2018-03-13: SCYNEXIS Reports FY17 EPS \$(0.94) vs \$(0.99) Est., Sales \$257K vs \$90K Est.

Financial news for SCYX dated on 2018-03-06: SCYNEXIS Prices Offering At \$1.69/Share For Expected Gross Proceeds ~\$30M

Financial news for SCYX dated on 2018-03-05: SCYNEXIS Shares Down 12% After Hours Following Launch Of Offering Of Common Shares, Warrants, No Amount Disclosed

Financial news for SCYX dated on 2018-03-05: SCYNEXIS Reports Launch Of Offering Of Common Shares, Warrants, No Amount Disclosed

Financial news for SCYX dated on 2018-02-01: UPDATE: SCYNEXIS Sees Phase 2 Trial In Invasive Aspergillosis Expected To Be Initiated In Q3'18

Financial news for SCYX dated on 2018-02-01: SCYNEXIS Reports New In Vivo Data Showing 'synergistic activity and improved outcomes of SCY-078 in combination with isavuconazole'

Financial news for SCYX dated on 2018-01-05: 30 Stocks Moving In Friday's Mid-Day Session

Financial news for SCYX dated on 2017-11-07: SCYNEXIS Reports Q3 EPS \$(0.31) vs \$(0.34) Est., Sales \$64K vs \$64K In Same Qtr. Last Year

Financial news for SCYX dated on 2017-10-24: Guggenheim Initiates Coverage On SCYNEXIS with Buy Rating, Announces \$6.00 Price Target

Financial news for SCYX dated on 2017-10-05: SCYNEXIS Reports New Data On SCY-078 For Potential Treatment For Aspergillus, Candida Infections: 'In vivo and in vitro data show SCY-078's favorable profile and potential therapeutic benefit'

Financial news for SCYX dated on 2017-08-17: Scynexis CEO Buys 10,000 @ Avg Price: \$1.61 -Form4

Financial news for SCYX dated on 2017-08-08: SCYNEXIS Reports Q2 EPS \$(0.16) vs \$(0.31) Est., Sales \$64K vs \$60K Est.

Financial news for SCYX dated on 2017-08-08: SCYNEXIS Reports Dosing Initiated In SCY-078 Phase 2 Study

Financial news for SCYX dated on 2017-08-03: SCYNEXIS Reports Initiation Of Dosing In Phase 2 Study Evaluating Oral SCY-078 In Vulvovaginal Candidiasis

Financial news for SCYX dated on 2017-06-15: SCYNEXIS Reports New Study Shows In Vitro Activity Of Co.'s SCY-078 Against Drug-Resistant Candida Fungal Strains

Financial news for SCYX dated on 2017-06-05: SCYNEXIS Reports 'Multiple studies confirm high compatibility of SCY-078 with other antifungals and favorable safety profile'

Financial news for SCYX dated on 2017-05-11: SCYNEXIS Reports Potent In Vitro Activity Of SCY-078 In CDC Study

Financial news for SCYX dated on 2017-05-09: Mid-Afternoon Market Update: Crude Oil Down 1%; CPI Aerostructures Shares Spike Higher

Financial news for SCYX dated on 2017-05-09: 20 Biggest Mid-Day Losers For Tuesday

Financial news for SCYX dated on 2017-05-09: Mid-Day Market Update: TravelCenters Drops After Q1 Results; Wayfair Shares Climb

Financial news for SCYX dated on 2017-05-09: Mid-Morning Market Update: Markets Open Higher; Dean Foods Earnings Miss Views

Financial news for SCYX dated on 2017-04-25: SCYNEXIS Reports Will Offer 8 Data Presentations at ECCMID Showcase: Presentations Will Support SCY-078's Potential as Novel Treatment for Candida Infections Including Multidrug-Resistant Strains

Financial news for SCYX dated on 2017-04-24: 18 Biggest Mid-Day Gainers For Monday

Financial news for SCYX dated on 2017-04-24: 25 Stocks Moving In Monday's Pre-Market Session

Financial news for SCYX dated on 2017-03-13: SCYNEXIS Reports FY16 EPS \$(1.58) vs \$(1.60) Est., Cash and Cash Equivalents, Short-Term Investments Totaled \$58.6M as of Dec. 31, 2016

Financial news for SCYX dated on 2017-03-03: Mid-Afternoon Market Update: Immersion Drops After Q4 Results; Snap Shares Spike Higher

Financial news for SCYX dated on 2017-03-03: 15 Biggest Mid-Day Losers For Friday

Financial news for SCYX dated on 2017-03-03: Mid-Day Market Update: Nutanix Drops On Weak Guidance; BioScrip Shares Climb

Financial news for SCYX dated on 2017-03-03: Mid-Morning Market Update: Markets Edge Lower; Big Lots Profit Beats Estimates

Financial news for SCYX dated on 2017-03-03: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for SCYX dated on 2017-03-02: SCYNEXIS Shares to Resume Trade at 4:35 p.m. EST

Financial news for SCYX dated on 2017-03-02: SCYNEXIS Delays Start Of New Clinical Studies Using IV Formulation Of SCY-078 At FDA's Request

Financial news for SCYX dated on 2017-03-02: SCYNEXIS Shares Halted News Pending

Financial news for SCYX dated on 2017-01-31: Aegis Initiating Coverage On Scynexis With Buy and \$7 PT

Financial news for SCYX dated on 2017-01-26: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for SCYX dated on 2016-12-22: SCYNEXIS INC: Taglietti Marco (Director, Chief Executive Officer) Buys 25,000 @ Avg Price: \$3.30 (Form4)

Financial news for SCYX dated on 2016-12-13: SCYNEXIS Achieves New Development Milestones Reinforcing the Versatility of SCY-078 in Treating Serious Fungal Infections

Financial news for SCYX dated on 2016-11-29: Reminder: SCYNEXIS Phase 1 Data On SCY-078 Expected By End Of Day Nov. 30th

Financial news for SCYX dated on 2016-11-07: SCYNEXIS Reports Q3 EPS \$(0.48) vs. Est. \$(0.50), Rev. \$64k vs. Est. \$70K

Financial news for SCYX dated on 2016-10-25: SCYNEXIS Completes Two Additional Clinical Studies Further Supporting the Favorable Safety Profile of SCY-078

Financial news for SCYX dated on 2016-10-20: Benzinga's Top Initiations

Financial news for SCYX dated on 2016-10-20: H.C. Wainwright Initiates Coverage On SCYNEXIS, Inc. - Common Stock at Buy, Announces \$14.00

Financial news for SCYX dated on 2016-10-07: WBB Securities Upgrades SCYNEXIS to Strong Buy

Financial news for SCYX dated on 2016-10-06: 12 Biggest Mid-Day Gainers For Thursday

Financial news for SCYX dated on 2016-10-06: Volatile Trading Seen In SCYNEXIS Amid Favorable Trial News

Financial news for SCYX dated on 2016-10-06: 18 Stocks Moving In Thursday's Pre-Market Session

Financial news for SCYX dated on 2016-10-05: SCYNEXIS Reports Results Confirm Antifungal Activity Of Oral SCY-078, Well-Tolerated And Active Oral Dose

Financial news for SCYX dated on 2016-10-03: Brean Assumes SCYNEXIS Shares At Buy, Sees 300% Upside

Financial news for SCYX dated on 2016-10-03: Brean Capital Assumes SCYNEXIS at Buy, Announces \$16.00 PT

Financial news for SCYX dated on 2016-09-26: Bio Pharma Companies Expected To Report Data By Friday Sept. 30 Include Genoea Biosciences, SCYNEXIS, Threshold Pharmaceuticals, Arbutus Biopharma, Cytori Therapeutics, Esperion Therapeutics, Mesoblast, Marinus Pharmaceuticals, & Syndax Pharmaceuticals

Financial news for SCYX dated on 2016-09-20: 30 Stocks With Three-Day Increasing Volume

Financial news for SCYX dated on 2016-09-20: 15 Stocks Which Rallied Three Days On Increasing Volume

Financial news for SCYX dated on 2016-08-24: 18 Biggest Mid-Day Gainers For Wednesday

Financial news for SCYX dated on 2016-08-24: SCYNEXIS Reports Orphan Drug Designation for SCY-078 for Treatment of Invasive Aspergillus Infections

Financial news for SCYX dated on 2016-08-24: 14 Stocks Moving In Wednesday's Pre-Market Session

Financial news for SCYX dated on 2016-08-18: 15 Biggest Mid-Day Gainers For Thursday

Financial news for SCYX dated on 2016-08-18: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for SCYX dated on 2016-08-17: 18 Biggest Mid-Day Gainers For Wednesday

Financial news for SCYX dated on 2016-08-17: Mid-Day Market Update: Urban Outfitters Surges Following Upbeat Results; 21Vianet Shares Slide

Financial news for SCYX dated on 2016-08-17: Benzinga's Top Initiations

Financial news for SCYX dated on 2016-08-17: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for SCYX dated on 2016-08-17: Guggenheim Securities Initiates Coverage on SCYNEXIS at Buy

Financial news for SCYX dated on 2016-08-09: WBB Securities Upgrades SCYNEXIS to Buy

Financial news for SCYX dated on 2016-08-08: SCYNEXIS Reports Q2 EPS \$(0.56) vs \$(0.52) Est., Sales \$64K vs \$90K Est.

Financial news for SCYX dated on 2016-08-01: SCYNEXIS Oral SCY-078 Achieves Target Exposure With Favorable Safety And Tolerability in Patients with Invasive Candidiasis

Financial news for SCYX dated on 2016-08-01: 15 Stocks Moving In Monday's Pre-Market Session

Financial news for SCYX dated on 2016-08-01: SCYNEXIS Announces Interim Results from Phase 2 Study of Oral SCY-078 in Patients with Invasive Candidiasis, Met All Primary Endpoints

Financial news for SCYX dated on 2016-07-13: SCYNEXIS, Inc. Announces Sale of Cyclophilin Inhibitor Assets to Cypralis Limited, Terms Not Disclosed

Financial news for SCYX dated on 2016-06-28: CEO Taglietti Buys 100,000 Shares of Scynexis @\$2.39/Share -Form 4

Financial news for SCYX dated on 2016-06-21: 8 Biggest Mid-Day Losers For Tuesday

Financial news for SCYX dated on 2016-06-21: Mid-Day Market Update: Crude Oil Down 2%; American Science & Engineering Shares Surge On Acquisition News

Financial news for SCYX dated on 2016-06-21: Mid-Morning Market Update: Markets Open Higher; CarMax Misses Q1 Estimates

Financial news for SCYX dated on 2016-06-21: SCYNEXIS Prices 9.375M Share Offering at \$2.40/Share

Financial news for SCYX dated on 2016-06-21: 12 Stocks Moving In Tuesday's Pre-Market Session

Financial news for SCYX dated on 2016-06-20: SCYNEXIS Reports Public Offering of Common Stock and Warrants

Financial news for SCYX dated on 2016-06-20: UPDATE: SCYNEXIS Says SCY-078 Has Shown 'to be the first glucan synthase inhibitor with high oral bioavailability in humans'

Financial news for SCYX dated on 2016-06-20: SCYNEXIS Reports Presentation of New Clinical, Non-Clinical Data Showing SCY-078 Potential as Novel Treatment for Life-Threatening Fungal Infections

Financial news for SCYX dated on 2016-06-09: 11 Biggest Mid-Day Losers For Thursday

Financial news for SCYX dated on 2016-06-09: Mid-Day Market Update: Restoration Hardware Falls Following Earnings Miss; Jaguar Animal Health Shares Jump

Financial news for SCYX dated on 2016-06-08: SCYNEXIS, Inc. Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors

Financial news for SCYX dated on 2016-05-13: SCYNEXIS Gets Orphan Drug Status For SCY-078

Financial news for SCYX dated on 2016-05-13: SCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Candida Infections

Financial news for SCYX dated on 2016-05-09: SCYNEXIS Reports Q1 EPS \$(0.52) vs. Est. \$(0.63), Rev. \$64K vs. Est. \$100K

Financial news for SCYX dated on 2016-04-19: SCYNEXIS Gets SME Designation From European Medicines Agency

Financial news for SCYX dated on 2016-04-19: SCYNEXIS Reports Received Designation as Small, Medium Enterprise by EMA

Financial news for SCYX dated on 2016-04-15: SCYNEXIS Offers Data Showing Support for Activity of SCY-078 Against Antifungal-Resistant Candida Strains

Financial news for SCYX dated on 2016-03-28: Benzinga's Top Initiations

Financial news for SCYX dated on 2016-03-28: Brean Initiates SCYNEXIS With Buy Rating, \$16 Price Target

Financial news for SCYX dated on 2016-03-28: Brean Capital Initiates Coverage on SCYNEXIS at Buy, Announces \$16.00 PT

Financial news for SCYX dated on 2016-03-21: SCYNEXIS Says on March 16, 2016, Yves J. Ribeill, Ph.D. Announced he had Resigned from SCYNEXIS Board of Directors Effective Immediately

Financial news for SCYX dated on 2016-03-14: Stocks Hitting 52-Week Lows

Financial news for SCYX dated on 2016-03-07: Stocks Hitting 52-Week Lows

Financial news for SCYX dated on 2016-03-07: SCYNEXIS Reports FY15 EPS \$(2.68) vs \$(2.66) Est., Sales \$257K vs \$50K Est.

Financial news for SCYX dated on 2016-01-28: SCYNEXIS, Inc. Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections

Financial news for SCYX dated on 2016-01-08: 12 Biotechs With Binary Events Coming This Year

Financial news for SCYX dated on 2015-12-30: Benzinga's Top Initiations

Financial news for SCYX dated on 2015-12-29: Benzinga's Top Initiations

Financial news for SCYX dated on 2015-12-29: SCYNEXIS Shares Volatile, Rally ~11%; WBB Securities Earlier Started at Speculative Buy, \$8 Target

Financial news for SCYX dated on 2015-12-01: SCYNEXIS Reports Initiation of Enrollment in Phase 2 Study of SCY-078 in Vulvovaginal Candidiasis

Financial news for SCYX dated on 2015-11-17: Filing from Scynexis Shows Registration for \$40M Common Stock Offering

Financial news for SCYX dated on 2015-11-13: SCYNEXIS Reports Q3 EPS (\$0.60) vs. Est. (\$0.62)



Financial news for SCYX dated on 2015-11-12: SCYNEXIS, Inc. Announces Initiation of Phase 1 Clinical Trial Evaluating Intravenous Formulation of SCY-078

Financial news for SCYX dated on 2015-11-02: SCYNEXIS Names Eric Francois as Chief Financial Officer

Financial news for SCYX dated on 2015-11-02: 8-K from Scynexis Shows Co. Named Eric Francois as New CFO

Financial news for SCYX dated on 2015-10-07: Scynexis Appoints Rajeshwar Motheram To Vice President, Pharmaceutical Development

Financial news for SCYX dated on 2015-09-28: SCYNEXIS, Inc. Announces Board of Directors Transitions

Financial news for SCYX dated on 2015-09-21: SCYNEXIS Shows Data Supporting the Potential Clinical Utility of Antifungal Drug Candidate at ICAAC/ICC 2015

Financial news for SCYX dated on 2015-07-23: SCYNEXIS, Inc. to Focus on SCY-078 Development

Financial news for SCYX dated on 2015-06-10: Needham Initiates Coverage on SCYNEXIS at Buy, Announces \$16.00 PT

Financial news for SCYX dated on 2015-05-27: Broadfin Capital Initiates 5.6% Passive Stake In SCYNEXIS

Financial news for SCYX dated on 2015-04-23: Morning Market Gainers

Financial news for SCYX dated on 2015-04-22: SCYNEXIS Prices ~4.675M Share Offering @\$7.70/Share

Financial news for SCYX dated on 2015-04-20: Amended S-1 from Scynexis Shows Launch of Common Stock Offering, Net Proceeds ~\$27M

Financial news for SCYX dated on 2015-04-09: Scynexis S-1 Shows Filing Of \$30M Stock Offer Via RBC Capital, Canaccord, JMP and Needham

Financial news for SCYX dated on 2015-03-26: SCYNEXIS Trading Resumed

Financial news for SCYX dated on 2015-03-26: SCYNEXIS Trading Halted

Financial news for SCYX dated on 2015-02-06: SCYNEXIS Names Marco Taglietti as CEO, Announces Chief Medical Officer Has Submitted Resignation

Financial news for SCYX dated on 2015-01-09: Scynexis Announces Fast Track Designation for SCY-078

Financial news for SCYX dated on 2014-12-03: SCYNEXIS, Inc. Announces Appointment Of Two Seasoned Industry Professionals To Its Board of Directors

Financial news for SCYX dated on 2014-11-13: Scynexis Reports Q3 EPS of \$(0.45) vs \$(0.53) Est

Financial news for SCYX dated on 2014-11-03: SCYNEXIS Inc. Enters Into Worldwide Agreement With Waterstone Pharmaceutical

Financial news for SCYX dated on 2014-08-13: Scynexis Reports Q2 EPS of \$(0.98) vs \$(0.40) Est; Revenue of \$4.64M vs \$4.0M Est

Financial news for SCYX dated on 2014-08-07: SCYNEXIS Shares Spike Higher; Halted on Circuit Breaker

Financial news for SCYX dated on 2014-06-02: Benzinga's Top Initiations

Financial news for SCYX dated on 2014-06-02: JMP Securities Initiates Coverage on Scynexis at Market Perform, Announces \$15.00 PT

Financial news for SCYX dated on 2014-05-29: Canaccord Genuity Initiates Coverage on Scynexis at Buy, Announces \$18.00 PT

Financial news for SCYX dated on 2014-05-29: Canaccord Genuity Initiates Coverage on Scynexis at Buy, Announces \$18.00 PT

Financial news for SCYX dated on 2014-05-29: RBC Capital Initiates Coverage on Scynexis at Outperform, Announces \$17.00 PT

Financial news for SCYX dated on 2014-05-05: IPO Lookout For The Week Of May 5: Alder Biopharma, Cheetah Mobile, GasLog Partners

Financial news for SCYX dated on 2014-05-02: Shares of SCYNEXIS Open for Trade Around \$9.75/Share, Priced at \$10

Financial news for SCYX dated on 2014-05-02: SCYNEXIS Reports Pricing of IPO, 6.2M Shares at \$10/Share

Financial news for SCYX dated on 2014-04-12: IPO Review For The Week Of April 7: IPOs Outperform S&P 500...Again

Financial news for SCYX dated on 2014-04-11: IPO Outlook for Friday, April 11: City Office, Paycom Software, Farmland Partners & More

Financial news for SCYX dated on 2014-04-07: IPO Lookout: IPOs For The Week Of April 7, 2014

Financial news for SCYX dated on 2014-03-31: IPO Lookout: IPOs for the Week of March 31

Financial news for SCYX dated on 2014-03-19: Scynexis Sees 4.2M Share IPO Priced \$12.00-\$14.00 -S-1/A